80 likes | 191 Views
Some examples from New Zealand. FIGURE 2. Regional meningococcal disease burden in New Zealand in 2002. O’Hallahan J, Lennon D, Oster P. The strategy to control New Zealand’s epidemic of group B meningococcal disease . PIDJ 2004;23 (12 Suppl):S293-8. Outer Membrane Vesicle vaccines.
E N D
FIGURE 2. Regional meningococcal diseaseburden in New Zealand in 2002. O’Hallahan J, Lennon D, Oster P.The strategy to control New Zealand’s epidemic of group B meningococcal disease. PIDJ 2004;23 (12 Suppl):S293-8
New Zealand epidemic subtypeP1.7b,4 Norwegian epidemic subtypeP1.7,16 (MenBvac) Oster P, Lennon D, O'Hallahan J, et al. MeNZBTM: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23(17-18):2191-2196.
In infants, the immune response measured as SBA is more strain-specific than in older children and adults. Vaccine strain Norwegian vaccine Holst J, Feiring B, Næss LM, Norheim G, Kristiansen P, Hoiby EA et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23(17-18):2202-2205.
Penicillin MICs 1995 - 2005 CLSI (NCCLS) breakpoints introduced in 2005